24/7 Market News Snapshot 14 May, 2025 – Inozyme Pharma, Inc. Common Stock (NASDAQ:INZY)

May 14, 2025

DENVER, Colo., 14 May, 2025 (www.247marketnews.com) – (NASDAQ:INZY) are discussed in this article.
Inozyme Pharma, Inc. is witnessing a significant rise in investor interest, with shares opening at $1.06 and trading at $1.255, reflecting a notable increase of 15.14%. The previous day’s close was at $1.090, showcasing a strong bullish momentum. With a trading volume of 2.23 million shares, market dynamics indicate heightened confidence among investors, supported by technical indicators that highlight potential resistance near $1.30 and support levels around $1.10. Continued positive momentum may suggest sustained price appreciation, making it essential for investors to observe volume trends and overall market sentiment for future price movements.

In conjunction with this market performance, Inozyme Pharma recently announced encouraging interim results from its pivotal ENERGY 3 trial, assessing the investigational drug INZ-701 for pediatric patients diagnosed with ENPP1 Deficiency. This trial milestone showcases INZ-701’s capacity to meaningfully impact the course of the disease, achieving substantial and sustained increases in phosphate levels while maintaining a favorable safety and immunogenicity profile. Notably, the trial has not experienced patient dropouts or dose adjustments, indicating strong treatment tolerance.

Dr. Douglas A. Treco, CEO and Chairman, expressed optimism regarding the ongoing results from the ENERGY 3 trial, emphasizing the significance of the emerging profile of INZ-701 in addressing ENPP1 Deficiency, a condition currently lacking approved treatment options. With enrollment for the trial finalized in January 2025 and topline data anticipated in the first quarter of 2026, positive biomarker data bolsters the hypothesis that INZ-701 may enhance long-term skeletal health through effective phosphate level management.

Moreover, Inozyme has expanded its leadership team, appointing Dr. Petra Duda as Chief Medical Officer, effective May 15, 2025. Dr. Duda’s extensive experience will be pivotal in directing INZ-701’s clinical development and aligning the company with its strategic objectives. The acceptance of new ICD-10 codes for ENPP1 Deficiency and an established regulatory strategy agreement with Japan’s PMDA further indicate Inozyme’s commitment to addressing critical unmet needs in the realm of rare diseases, particularly in bone health and vascular function.

Related news for (INZY)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.